Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -1,10k | 166,63k | Automatic Disposition | 151,48 | 14,27k | -7,16% |
| 2026-06-01 | Mr. Thomas E. PolenPresident, CEO & Chairman | -20,21k | 404,53k | Derivative Exercise and Sale | 126,16 - 146,35 | 110,16k | - |
| 2026-05-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -75,00 | 11,05k | Automatic Disposition | 147,35 | 21,08k | -0,35% |
| 2026-04-27 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -74,00 | 11,24k | Automatic Disposition | 151,94 | 21,16k | -0,35% |
| 2026-04-06 | Ms. Shana Carol NealExec. VP & CPO | -1,15k | 0,00 | Sale to Issuer | - | 23,97k | -4,56% |
| 2026-03-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -75,00 | 11,76k | Automatic Disposition | 156,83 | 21,23k | -0,35% |
| 2026-02-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -75,00 | 13,64k | Automatic Disposition | 181,84 | 21,31k | -0,35% |
| 2026-02-18 | Mr. Bertram Lee ScottIndependent Director | -953,00 | 174,03k | Vente | 182,61 | 36,76k | -2,53% |
| 2026-01-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -75,00 | 15,20k | Automatic Disposition | 202,73 | 16,43k | -0,45% |
| 2026-01-21 | Ms. Pamela L. SpiknerInitié | -84,00 | 0,00 | Sale to Issuer | - | 1,83k | -4,38% |
| 2026-01-15 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -3,05k | 125,49k | Derivative Exercise and Sale | 167,91 - 209,00 | 12,10k | - |
| 2026-01-15 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -1,01k | 208,61k | Automatic Disposition | 206,54 | 12,10k | -7,71% |
| 2026-01-03 | Mr. David Michel ShanExec. VP & Chief Integrated Supply Chain Officer | -44,00 | 0,00 | Sale to Issuer | - | 8,93k | -0,49% |
| 2025-12-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -74,00 | 14,51k | Automatic Disposition | 196,08 | 16,51k | -0,45% |
| 2025-12-17 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -629,00 | 123,30k | Automatic Disposition | 196,03 | 13,11k | -4,58% |
| 2025-12-01 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -75,00 | 14,50k | Automatic Disposition | 193,36 | 16,58k | -0,45% |
| 2025-11-26 | Mr. David Michel ShanExec. VP & Chief Integrated Supply Chain Officer | -134,00 | 0,00 | Sale to Issuer | - | 8,97k | -1,47% |
| 2025-11-26 | Ms. Shana Carol NealExec. VP & CPO | -2,45k | 0,00 | Sale to Issuer | - | 21,33k | -10,32% |
| 2025-11-26 | Mr. Roland GoetteExec. VP & President of EMEA | -138,00 | 0,00 | Sale to Issuer | - | 18,78k | -0,73% |
| 2025-11-26 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -1,77k | 0,00 | Sale to Issuer | - | 13,73k | -11,41% |
| 2025-11-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -419,00 | 0,00 | Sale to Issuer | - | 16,66k | -2,45% |
| 2025-11-26 | Mr. Christopher J. DelOreficeInitié | -4,25k | 0,00 | Sale to Issuer | - | 22,98k | -15,59% |
| 2025-11-26 | Mr. Richard E. ByrdInitié | -1,72k | 0,00 | Sale to Issuer | - | 13,85k | -11,04% |
| 2025-11-26 | Mr. Thomas E. PolenPresident, CEO & Chairman | -17,42k | 0,00 | Sale to Issuer | - | 105,47k | -14,18% |
| 2025-11-07 | Mr. Bertram Lee ScottIndependent Director | -217,00 | 38,32k | Vente | 176,58 | 35,82k | -0,60% |
| 2025-10-27 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -57,00 | 10,60k | Automatic Disposition | 186,01 | 8,25k | -0,69% |
| 2025-09-26 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -58,00 | 10,50k | Automatic Disposition | 181,03 | 8,30k | -0,69% |
| 2025-09-10 | Dr. Claire M. Fraser-LiggettInitié | -917,00 | 171,94k | Vente | 187,50 | 22,23k | -3,96% |
| 2025-09-01 | Mr. Christopher J. DelOreficeInitié | -278,00 | 0,00 | Sale to Issuer | - | 21,22k | -1,29% |
| 2025-09-01 | Mr. Richard E. ByrdInitié | -216,00 | 0,00 | Sale to Issuer | - | 6,74k | -3,11% |
| 2025-08-22 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -57,00 | 11,29k | Automatic Disposition | 197,99 | 8,36k | -0,68% |
| 2025-08-20 | Mr. Michael C. FeldExec. VP & Chief Revenue Officer | -773,00 | 0,00 | Sale to Issuer | - | 8,42k | -8,41% |
| 2025-08-11 | Mr. Gregory J. HayesIndependent Director | 5,25k | 1,01M | Achat | 191,57 | 5,25k | - |
| 2025-08-08 | Dr. Claire M. Fraser-LiggettInitié | -863,00 | 165,95k | Vente | 192,30 | 23,14k | -3,59% |
| 2025-07-18 | Mr. Michael GarrisonExec. VP & President of Medical Segment and BioPharma Systems Segments | -6,36k | 207,40k | Derivative Exercise and Sale | 147,68 - 181,50 | 4,89k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
